Deciphering the Causes of Cardiovascular and Other Complex Diseases in Populations: Achievements, Challenges, Opportunities, and Approaches

Progress in Cardiovascular Diseases

Volumn 53, Issue 1, 2010, Pages 62-67

  Yusuf, Salim ^a   Anand, Sonia ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Cardiovascular diseases; Causes; Prevention; Risk factors

Indexed keywords

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMUNITY SAMPLE; DEVELOPING COUNTRY; ETHNIC DIFFERENCE; GENOTYPE ENVIRONMENT INTERACTION; HEALTH BEHAVIOR; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MARKER GENE; MEDICAL RESEARCH; POPULATION RESEARCH; PROGNOSIS; RISK REDUCTION; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM; URBAN RURAL DIFFERENCE; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEALTH SURVEY; HISTORY; NATIONAL HEALTH ORGANIZATION; PUBLIC HEALTH; RISK ASSESSMENT; RISK FACTOR; TIME; UNITED STATES;

CARDIOVASCULAR DISEASES; EPIDEMIOLOGIC RESEARCH DESIGN; EVIDENCE-BASED MEDICINE; HEALTH POLICY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NATIONAL HEALTH PROGRAMS; NATIONAL INSTITUTES OF HEALTH (U.S.); POPULATION SURVEILLANCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 77954171380     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.02.001     Document Type: Article

References (18)

1. Yusuf S., Reddy S., Ôunpuu S., et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001, 104:2746-2753.
2. Kannel W.B., Castelli W.P., McNamara P.M. The coronary profile: 12-year follow-up in the Framingham study. J Occup Med 1967, 9:611-619.
3. D'Agostino R.B., Grundy S., Sullivan L.M., et al. CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187.
4. Truett J., Cornfield J., Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis 1967, 20:511-524.
5. Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113:791-798.
6. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
7. Kelemen L.E., Anand S.S., Hegele R.A., et al. Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. Atherosclerosis. 2004, 176:361-370.
8. Teo K.K., Ounpuu S., Hawken S., et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006, 368:647-658.
9. Anstey K.J., Lipnicki D.M., Low E.F. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 2008, 16:343-354.
10. Nagai M., Hoshide S., Kario K. Hypertension and dementia. Am J Hypertens 2010, 23:116-124.
11. Peters R., Poulter R., Warner J., et al. Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatrics 2008, 8:36-42.
12. Chow C.K., Lock K., Teo K., et al. Environmental and societal influences acting on cardiovascular risk factors and disease at a population level: a review. Int J Epidemiol 2009, 38:1580-1594.
13. Engert J.C., Do R., Zhang X., et al. Diet modifies the myocardial infarction risk of chromosome 9p21 variants globally 2009.
14. Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation. Eur J Epidemiol 2008, 23:531-540. CRP CHD Genetics Collaboration.
15. Herbst A.L., Ulfelder H., Poskanzer D.C. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971, 284:878-881.
16. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002, 360:2-3.
17. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419.
18. Indian Polycap Study (TIPS), Yusuf S., Pais P., et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009, 373:1341-1351.